Revance Therapeutics Inc (RVNC)

[DewDiligence]

The “double dose” canard is just that. Slide #20 in RVNC’s latest corporate slide set (https://investors.revance.com/static-files/8d1f2575-2f62-4f78-8044-abcf5fd06ada ) shows that 40U of Daxxify has the same amount of active toxin as 20U of Botox. The same amount, not twice as much.

Further, for glabellar lines specifically, the dose-limiting factor is ptosis. Daxxify at its 40U labeled dose does not produce more ptosis than Botox at its 20U labeled dose. In fact, Daxxify produces ptosis in a smaller proportion of patients than Botox: #msg-157639118, #msg-160262702.

RVNC’s competitors, including EOLS, will continue to try to hoodwink investors with the double-dose canard to divert attention from the manifest inferiority of their own products. EOLS is even running a trial testing a doubled dose of Jeaveau in glabellar lines. This trial, which will read out in mid 2023, will show that doubling the dose of Jeuveau leads to a slightly longer duration of effect—but not as long a duration as Daxxify at Daxxify's regular (labeled) dose. Moreover, the doubled dose of Jeuveau will likely show an unacceptably high rate of ptosis.